The added value of [Ga-68]Ga-DOTA-FAPI-04 PET/CT in pancreatic cancer: a comparison to [F-18]F-FDG

ObjectivesWe aimed to compare the diagnostic and prognostic performance of [Ga-68]Ga-DOTA-FAPI-04 and [F-18]FDG PET/CT in pancreatic cancer.MethodsThis single-center retrospective study enrolled 51 patients who underwent [Ga-68]Ga-DOTA-FAPI-04 and [F-18]FDG PET/CT. The final diagnosis on PET/CT images was verified by histopathology or 1-year follow-up. The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy of [F-18]FDG and [Ga-68]Ga-DOTA-FAPI-04 PET/CT were calculated to compare the diagnostic efficacy. Progression-free survival (PFS) was the endpoint for the survival analysis. Twenty-six patients were eligible for the Kaplan-Meier survival analysis using a log-rank test. And multivariate analysis including age, sex, stage, CA199 level, and SUVmax of [F-18]FDG and [Ga-68]Ga-DOTA-FAPI-04 was also performed. Two-tailed p < 0.05 was considered statistically significant.Results[Ga-68]Ga-DOTA-FAPI-04 showed a higher sensitivity than [F-18]FDG for detecting primary tumor (100% vs. 95.0%), metastatic lymph nodes (96.2% vs. 61.5%), and distant metastases (100% vs. 84.0%) (p < 0.0001, respectively). For [Ga-68]Ga-DOTA-FAPI-04, the tumor-to-liver background ratio (TLBR) of liver metastases was higher (5.7 +/- 3.2 vs. 3.2 +/- 1.3, p < 0.0001). Furthermore, SUVmax > 14.9 on [Ga-68]Ga-DOTA-FAPI-04 was significantly associated with PFS rates (chi-square = 12.05, p = 0.001). The Cox regression analysis showed that SUVmax of [Ga-68]Ga-DOTA-FAPI-04 was an independent prognostic factor for PFS (p = 0.001; hazard ratio, 8.877).Conclusions[Ga-68]Ga-DOTA-FAPI-04 PET/CT showed a higher sensitivity and accuracy than [F-18]FDG PET/CT in diagnosing pancreatic cancer and might have an independent prognostic value for pancreatic cancer patients.